Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 5Parasomnias 3Neoplasms 3Tuberous Sclerosis 2Smith-Magenis Syndrome 2Lung Neoplasms 2Autism Spectrum Disorder 2Angelman Syndrome 2Weight Loss 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Sleep Disorders, Circadian Rhythm 1Relapsed Malignant Solid Tumor 1Radiodermatitis 1Radiation Injuries 1Polycystic Ovary Syndrome 1Pain 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fatigue 1Depression 1Delirium 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Brain Neoplasms 1Barrett Esophagus 1Anorexia 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms × Melatonin × Clear all
NCT00925899 2017-04-20

Melatonin for Fatigue and Other Symptoms in Patients With Advanced Cancer

Bispebjerg Hospital

Phase 2/3 Completed
72 enrolled 11 charts

Fatigue, Neoplasms

NCT02200172 2016-07-19

The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study

Bruyère Health Research Institute.

Phase 2 Completed
60 enrolled

Delirium, Neoplasms

NCT01706627 2012-10-15

MIRCIT

Khon Kaen University

Phase 2/3 Completed
175 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡